Zhuhai Rundu Pharmaceutical Co., Ltd. (002923)
Market Closed
11 Aug, 06:57
XSHE XSHE Primary ¥
11. 49
0
0%
¥
4.76B Market Cap
- P/E Ratio
0.6% Div Yield
12.19M Volume
- Eps
¥ 11.49
Previous Close Want to track 002923 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
002923 closed today higher at ¥11.49, an increase of 0% from yesterday's close, completing a monthly increase of 20.9474% or ¥1.99. Over the past 12 months, 002923 stock lost -5.5099%.
002923 is not paying dividends to its shareholders.
The last earnings report, released on May 16, 2025, exceeded the consensus estimates by 0.0056%. On average, the company has surpassed earnings expectations by 0.0462%, based on the last three reports.
Zhuhai Rundu Pharmaceutical Co., Ltd. has completed 4 stock splits, with the recent split occurring on May 31, 2023.
The company's stock is traded on one exchange.
Zhuhai Rundu Pharmaceutical Co., Ltd. (002923) FAQ
What is the stock price today?
The current price is ¥11.49.
On which exchange is it traded?
Zhuhai Rundu Pharmaceutical Co., Ltd. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 002923.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.6%.
What is its market cap?
As of today, the market cap is 4.76B.
Has Zhuhai Rundu Pharmaceutical Co., Ltd. ever had a stock split?
Zhuhai Rundu Pharmaceutical Co., Ltd. had 4 splits and the recent split was on May 31, 2023.
Zhuhai Rundu Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Jie Liu CEO | XSHE Exchange | CNE1000033G8 ISIN |
| CN Country | 1,985 Employees | 30 May 2025 Last Dividend | 12 Jun 2019 Last Split | - IPO Date |
Overview
Zhuhai Rundu Pharmaceutical Co., Ltd. is a front-runner in the pharmaceutical industry, dedicated to the development, production, and commercialization of active pharmaceutical ingredients (APIs) and formulations across the globe. Since its inception in 1997, the company has systematically expanded its footprint in the domain of pharmaceuticals, anchoring its expertise particularly in therapeutic areas such as cardiovascular diseases, gastrointestinal disorders, and the central nervous system (CNS) ailments. With its headquarters in Zhuhai, China, Rundu Pharmaceutical has cemented its position as a key player in the pharmaceutical sector, delivering high-quality products and services worldwide.
Products and Services
- APIs (Active Pharmaceutical Ingredients) - Rundu Pharmaceutical specializes in the development and manufacture of APIs which are crucial for the production of various medicines. These ingredients play a pivotal role in the drug development process, offering essential properties needed for medications to treat various conditions.
- Intermediates - The company provides a wide range of intermediates that are used in the synthesis of more complex compounds. These intermediates are a vital component in the pharmaceutical manufacturing chain, enabling the production of APIs and final drug formulations.
- FDF (Finished Dosage Forms) - Rundu Pharmaceutical offers a diversified portfolio of finished dosage forms, which include tablets, capsules, and injectables, among others. These products are developed using the company’s in-house APIs and are designed to meet the highest standards of efficacy, safety, and quality.
- Pellets - The company also produces pellets, which are small, free-flowing, spherical or semi-spherical solid forms used in the manufacture of capsule dosage forms. These pellets ensure uniform distribution of the active ingredient in the gastrointestinal tract, thereby enhancing the drug's effectiveness.
Contact Information
Address: No. 6, North Airport Road, Zhuhai, China, 519041
Phone: 86 75 6763 0088
Website: https://www.rdpharma.cn
